Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is estimated to affect approximately 1 in 50,000 people worldwide. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia. This article will provide an overview of Friedreich ataxia, including its causes, symptoms, diagnosis, and treatments.
Friedreich ataxia is an inherited disorder that affects the nervous system and causes progressive physical and cognitive disability. It is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
The symptoms of Friedreich ataxia vary from person to person, but usually appear in childhood or adolescence. Common symptoms include: • Progressive loss of coordination, balance, and muscle strength • Loss of sensation in the extremities • Slurred speech and difficulty swallowing • Vision problems • Hearing loss • Heart problems • Fatigue • Scoliosis • Diabetes
Friedreich ataxia is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
Friedreich ataxia is usually diagnosed through a combination of physical examination, neurological testing, and genetic testing. Physical examination may reveal signs of muscle weakness, coordination problems, and scoliosis. Neurological testing may reveal impaired reflexes, muscle weakness, and balance problems. Genetic testing can confirm the presence of the FXN gene mutation.
There is currently no cure for Friedreich ataxia, but there are treatments available to help manage the symptoms. Treatment may include physical therapy, occupational therapy, speech therapy, and medications to help manage pain, fatigue, and other symptoms. Additionally, there are clinical trials underway to investigate potential treatments for Friedreich ataxia.
Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Diagnosis involves physical examination, neurological testing, and genetic testing, and treatments may include physical therapy, occupational therapy, speech therapy, and medications. While there is currently no cure for Friedreich ataxia, there are treatments available to help manage the symptoms and clinical trials underway to investigate potential treatments.
1.
Remote monitoring can improve recovery from cancer surgery
2.
Intractable cancers may respond better to treatment when using new radiation and high-performance computing.
3.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
4.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
5.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation